AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 76(6), 2007, pp. 1024-1026
Copyright © 2007 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by OSORIO, L.
Right arrow Articles by WITTLIN, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by OSORIO, L.
Right arrow Articles by WITTLIN, S.
Related Collections
Right arrow Malaria

IN VITRO SUSCEPTIBILITY OF P. FALCIPARUM POPULATIONS FROM COLOMBIA AND TANZANIA TO A NEW SYNTHETIC PEROXIDE (OZ277)

LYDA OSORIO*, CLARIBEL MURILLO, SAMANDA APONTE, VALERIANA MAYAGAYA, CHRISTIAN SCHEURER, RETO BRUN, HUGUES MATILE, AND SERGIO WITTLIN
International Center for Medical Research and Training (CIDEIM), Cali, Colombia; Ifakara Health Research & Development, Ifakara, Tanzania; Swiss Tropical Institute (STI), Basel, Switzerland; F. Hoffmann-La Roche Ltd., Basel, Switzerland

Sensitivity of Plasmodium falciparum populations from Colombia (N = 38) and Tanzania (N = 45) to the newly developed, fully synthetic peroxide OZ277 was investigated using a standard isotopic microtest. OZ277 showed excellent activity against chloroquine-resistant isolates in Colombia with median IC50 [range] values of 2.5 ng/mL [0.34–8] (4.4 nM [0.6–14]) and Tanzania with 1.5 ng/mL [0.22–10] (2.65 nM [0.4–17.7]). The potency of OZ277 was similar to artesunate, showing median IC50 values of 1.5 ng/mL [0.42–8.6] (3.8 nM [1.1–22.3]) and 1.8 ng/mL [0.2–10] (4.7 nM [0.5–26.04]) in Colombia and Tanzania, respectively. These results support the development of this new antimalarial compound.

Received September 4, 2006. Accepted for publication November 4, 2006.

Acknowledgments: We are grateful to Rubiela Giraldo, Monica Banguero, Claudia Quelal, and Meleny Ramirez, who collected the samples in Colombia, and to Marcel Tanner, Hassan Mshinda, and the diagnostic team from the Ifakara Health Research & Development Centre in Tanzania.

Financial support: This study was supported by the Medicines for Malaria Venture (MMV).

* Address correspondence to Lyda Osorio, International Center for Medical Research and Training (CIDEIM), Avenida 1 Norte #3-03, Cali, Colombia. E-mail: lydaosorio{at}cideim.org.co, lyda.osorio{at}lshtm.ac.uk

Authors’ addresses: Lyda Osorio, Claribel Murillo, and Samanda Aponte, International Center for Medical Research and Training (CIDEIM), Avenida 1 Norte #3-03, Cali, Colombia, Telephone: +57 2 668 2164, Fax: +57 2 667 2989, E-mail: lyda.osorio{at}cideim.org.co, claribel_murillo{at}cideim.org.co, and samanda_aponte{at}cideim.org.co. Valeriana Mayagaya, Ifakara Health Research & Development Centre, P.O. Box 53, Ifakara, Tanzania, Telephone: +255-23-2625164, E-mail: mayagaya6{at}yahoo.com. Christian Scheurer, Reto Brun, and Sergio Wittlin, Swiss Tropical Institute (STI), Socinstrasse 57, CH-4002 Basel, Switzerland, Telephone: +41-61-284-8136, Fax +41-61-284-8101, E-mail: christian.scheurer{at}unibas.ch, reto.brun{at}unibas.ch, and sergio.wittlin{at}unibas.ch. Hugues Matile, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, CH-4070 Basel, Switzerland, Telephone: +41-61- 688-3191, Fax: +41-61-688-2438, E-mail: hugues.matile{at}roche.com.

Reprint requests: Lyda Osorio, CIDEIM Avenida 1 Norte #3-03 Cali, Colombia.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Tropical Medicine and Hygiene.